A 41-year-old man with poorly controlled HIV (CD4 89/µL) presents with odynophagia, dysphagia to solids, and substernal burning for 10 days. Oral examination reveals white curd-like plaques on the tongue and buccal mucosa that scrape off to leave erythematous mucosa. The diagram shows the management algorithm for suspected esophageal candidiasis in this clinical context. The structure marked **A** represents the recommended initial therapeutic approach. Which of the following best describes the rationale and escalation strategy for the management pathway marked **A**?

Question

Accepted Answer

A. Empirical oral fluconazole 200–400 mg/day for 14–21 days; if refractory at 7–14 days, escalate to echinocandin or alternative azole (itraconazole, voriconazole, posaconazole). ## Why option 0 is correct

The clinical presentation of oral thrush (white curd-like plaques that scrape off) combined with esophageal symptoms (odynophagia, dysphagia) in a severely immunocompromised host (CD4 89/µL) has a positive predictive value >70% for Candida esophagitis. According to IDSA Candidiasis Guidelines 2016 and IDSA HIV OI Guidelines 2024, **empirical oral fluconazole 200–400 mg/day is first-line therapy** without the need for immediate endoscopy in this clinical scenario. The structure marked **A** encapsulates the evidence-based escalation strategy: if clinical improvement does not occur within 7–14 days, refractory disease is managed by switching to echinocandins (caspofungin, micafungin, anidulafungin—which inhibit β-1,3-glucan synthase in the fungal cell wall) or alternative azoles (itraconazole, voriconazole, posaconazole). This approach balances empiricism with cost-effectiveness and avoids unnecessary invasive investigation in the majority of cases.

## Why each distractor is wrong

- **Option 1 (IV ganciclovir)**: Ganciclovir is the treatment for CMV esophagitis, not Candida esophagitis. CMV typically presents with deep linear distal ulcers and intranuclear inclusions on biopsy, not the white adherent plaques characteristic of candidiasis. The clinical presentation here is classic for Candida, not CMV.

- **Option 2 (No treatment)**: Candida esophagitis is a treatable opportunistic infection that causes significant morbidity (odynophagia, dysphagia, malnutrition). Withholding antifungal therapy is inappropriate and contradicts IDSA guidelines. While immune reconstitution is essential, it does not substitute for antimicrobial therapy during the acute phase.

- **Option 3 (Surgical fundoplication)**: Fundoplication is a surgical intervention for gastroesophageal reflux disease, not for infectious esophagitis. Candida esophagitis is managed medically; surgery has no role in the acute management and is not indicated for this condition.

**High-Yield:** In a severely immunocompromised patient (CD4 <200) with oral thrush + esophageal symptoms, empirical fluconazole without endoscopy is standard; escalate to echinocandins only if refractory at 7–14 days.

[cite: IDSA Candidiasis Guidelines 2016; Pappas Clin Infect Dis 2016; IDSA HIV OI Guidelines 2024]

Answer

B. Surgical fundoplication to prevent reflux-induced esophageal injury and reduce recurrent candidiasis

Answer

C. Immediate IV ganciclovir 5 mg/kg BD, as CMV esophagitis is the most common cause of esophageal ulceration in this CD4 stratum

Answer

D. No antifungal therapy is necessary; oral thrush with esophageal symptoms resolves spontaneously with immune reconstitution alone

Explanation

Why option 0 is correct

Why each distractor is wrong

Practice similar questions